Sex-specific impact of diabetes on all-cause mortality among adults with acute myocardial infarction: An updated systematic review and meta-analysis, 1988-2021.
acute myocardial infarct (AMI)
all-cause mortality
diabetes mellitus
meta-analysis
sex-specific
systemic review
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
04
2022
accepted:
27
07
2022
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
The prevalence of diabetes and its impact on mortality after acute myocardial infarction (AMI) are well-established. Sex-specific analyses of the impact of diabetes on all-cause mortality after AMI have not been updated and comprehensively investigated. To conduct a systematic review and meta-analysis that examined sex-specific short-term, mid-term and long-term all-cause mortality associated with diabetes among AMI survivors (diabetes versus non-diabetes patients in men and women separately), using up-to-date data. We systematically searched Embase and MEDLINE for studies that were published from inception to November 14, 2021. Studies were included if (1) they studied post-AMI all-cause-mortality in patients with and without diabetes, (2) sex-specific all-cause mortality at short-term (in-hospital or within 90 days after discharge), mid-term (>90 days and within 5 years), and/or long-term (>5 years) were reported. From eligible studies, we used random effects meta-analyses models to estimate pooled unadjusted and adjusted sex-specific risk ratio (RR) of all-cause mortality at short-, mid-, and long-term follow-up for adults with diabetes compared with those without diabetes. Of the 3647 unique studies identified, 20 studies met inclusion criteria. In the unadjusted analysis (Total N=673,985; women=34.2%; diabetes patients=19.6%), patients with diabetes were at a higher risk for all-cause mortality at short-term (men: RR, 2.06; women: RR, 1.83); and mid-term follow-up (men: RR, 1.69; women: RR, 1.52) compared with those without diabetes in both men and women. However, when adjusted RRs were used (Total N=7,144,921; women=40.0%; diabetes patients=28.4%), the associations between diabetes and all-cause mortality in both men and women were attenuated, but still significantly elevated for short-term (men: RR, 1.16; 95% CI, 1.12-1.20; women: RR, 1.29; 95% CI, 1.15-1.46), mid-term (men: RR, 1.39; 95% CI, 1.31-1.46; women: RR, 1.38; 95% CI, 1.20-1.58), and long-term mortality (men: RR, 1.58; 95% CI, 1.22-2.05; women: RR, 1.76; 95% CI, 1.25-2.47). In men, all-cause mortality risk associated with diabetes tended to increase with the duration of follow-up (p<0.0001). Diabetes has substantial and sustained effects on post-AMI all-cause mortality at short-term, mid-term and long-term follow-up, regardless of sex. Tailoring AMI treatment based on patients' diabetes status, duration of follow-up and sex may help narrow the gap in all-cause mortality between patients with diabetes and those without diabetes.
Sections du résumé
Background
The prevalence of diabetes and its impact on mortality after acute myocardial infarction (AMI) are well-established. Sex-specific analyses of the impact of diabetes on all-cause mortality after AMI have not been updated and comprehensively investigated.
Objective
To conduct a systematic review and meta-analysis that examined sex-specific short-term, mid-term and long-term all-cause mortality associated with diabetes among AMI survivors (diabetes versus non-diabetes patients in men and women separately), using up-to-date data.
Methods
We systematically searched Embase and MEDLINE for studies that were published from inception to November 14, 2021. Studies were included if (1) they studied post-AMI all-cause-mortality in patients with and without diabetes, (2) sex-specific all-cause mortality at short-term (in-hospital or within 90 days after discharge), mid-term (>90 days and within 5 years), and/or long-term (>5 years) were reported. From eligible studies, we used random effects meta-analyses models to estimate pooled unadjusted and adjusted sex-specific risk ratio (RR) of all-cause mortality at short-, mid-, and long-term follow-up for adults with diabetes compared with those without diabetes.
Results
Of the 3647 unique studies identified, 20 studies met inclusion criteria. In the unadjusted analysis (Total N=673,985; women=34.2%; diabetes patients=19.6%), patients with diabetes were at a higher risk for all-cause mortality at short-term (men: RR, 2.06; women: RR, 1.83); and mid-term follow-up (men: RR, 1.69; women: RR, 1.52) compared with those without diabetes in both men and women. However, when adjusted RRs were used (Total N=7,144,921; women=40.0%; diabetes patients=28.4%), the associations between diabetes and all-cause mortality in both men and women were attenuated, but still significantly elevated for short-term (men: RR, 1.16; 95% CI, 1.12-1.20; women: RR, 1.29; 95% CI, 1.15-1.46), mid-term (men: RR, 1.39; 95% CI, 1.31-1.46; women: RR, 1.38; 95% CI, 1.20-1.58), and long-term mortality (men: RR, 1.58; 95% CI, 1.22-2.05; women: RR, 1.76; 95% CI, 1.25-2.47). In men, all-cause mortality risk associated with diabetes tended to increase with the duration of follow-up (p<0.0001).
Conclusions
Diabetes has substantial and sustained effects on post-AMI all-cause mortality at short-term, mid-term and long-term follow-up, regardless of sex. Tailoring AMI treatment based on patients' diabetes status, duration of follow-up and sex may help narrow the gap in all-cause mortality between patients with diabetes and those without diabetes.
Identifiants
pubmed: 36060979
doi: 10.3389/fendo.2022.918095
pmc: PMC9428712
doi:
Types de publication
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
918095Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK111022
Pays : United States
Informations de copyright
Copyright © 2022 Ding, Funk, Spatz, Lin, Batten, Wu and Whittemore.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Endocrinol (Lausanne). 2021 Dec 14;12:797049
pubmed: 34970227
Diabetes Care. 2012 Oct;35(10):2043-7
pubmed: 22815296
Diabetes Care. 2001 Aug;24(8):1422-7
pubmed: 11473080
Circulation. 2008 Apr 15;117(15):1945-54
pubmed: 18378618
JAMA. 1988 Dec 16;260(23):3456-60
pubmed: 2974889
Diabetologia. 2005 May;48(5):856-61
pubmed: 15827741
J Intern Med. 1997 Jun;241(6):485-92
pubmed: 10497624
Pol Arch Intern Med. 2021 Nov 30;131(11):
pubmed: 34581173
Lancet. 2010 Jun 26;375(9733):2215-22
pubmed: 20609967
Circulation. 2012 Aug 21;126(8):934-41
pubmed: 22829023
J Am Coll Cardiol. 2005 May 3;45(9):1413-8
pubmed: 15862411
Clin Diabetes. 2019 Oct;37(4):316-337
pubmed: 31660005
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Ann Med. 1996 Aug;28(4):323-33
pubmed: 8862687
BMC Public Health. 2010 Jun 14;10:338
pubmed: 20546579
J Am Heart Assoc. 2018 Jun 30;7(13):
pubmed: 29960995
Am Heart J. 1997 Mar;133(3):290-6
pubmed: 9060796
Diabetes Care. 2000 Jul;23(7):962-8
pubmed: 10895847
Lancet Diabetes Endocrinol. 2018 Jun;6(6):455-463
pubmed: 29567074
Diabetologia. 2004 Jul;47(7):1188-1195
pubmed: 15235772
Am J Cardiol. 2010 Dec 15;106(12):1680-4
pubmed: 21126609
Cardiovasc Diabetol. 2021 Apr 22;20(1):81
pubmed: 33888124
Am J Epidemiol. 2003 May 15;157(10):940-3
pubmed: 12746247
Circulation. 2015 Dec 22;132(25):2424-47
pubmed: 26644329
Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):791-7
pubmed: 23132330
Circ Cardiovasc Interv. 2015 Apr;8(4):e001944
pubmed: 25788342
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
Am Heart J. 1995 Jul;130(1):51-8
pubmed: 7611123
Arch Intern Med. 2004 Jul 12;164(13):1457-63
pubmed: 15249356
Hypertension. 1998 Oct;32(4):764-9
pubmed: 9774377
Diabetes Care. 1998 Jan;21(1):69-75
pubmed: 9538972
Am Heart J. 2003 Nov;146(5):824-31
pubmed: 14597931
N Engl J Med. 1998 Jul 23;339(4):229-34
pubmed: 9673301
Eur J Epidemiol. 2007;22(12):883-8
pubmed: 17926133
Cardiovasc Diabetol. 2012 Aug 11;11:96
pubmed: 22882797
Diabetes Care. 1997 May;20(5):704-8
pubmed: 9135930
Arch Intern Med. 2002 Aug 12-26;162(15):1737-45
pubmed: 12153377
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Diabetes Care. 1998 Aug;21(8):1258-65
pubmed: 9702430
Annu Rev Public Health. 1988;9:123-60
pubmed: 3288229
Diabetologia. 2012 Jan;55(1):80-7
pubmed: 21861177
J Am Coll Cardiol. 1993 Dec;22(7):1788-94
pubmed: 8245329
Diabetes Care. 2004 Dec;27(12):2898-904
pubmed: 15562204
J Cardiol. 2013 Jun;61(6):393-8
pubmed: 23499171
World J Cardiol. 2015 May 26;7(5):243-76
pubmed: 26015857
Circulation. 1991 Feb;83(2):484-91
pubmed: 1991367
Eur Heart J. 2003 May;24(9):838-44
pubmed: 12727151
Diabetes Res Clin Pract. 2015 May;108(2):216-22
pubmed: 25771308
Cardiovasc Res. 2002 Feb 15;53(3):709-19
pubmed: 11861041
BMJ. 2021 Mar 29;372:n160
pubmed: 33781993
Circulation. 2000 May 2;101(17):2040-6
pubmed: 10790344
Ann Intern Med. 2007 Aug 7;147(3):149-55
pubmed: 17576993
Intern Emerg Med. 2021 Nov;16(8):2109-2119
pubmed: 33713285
World J Diabetes. 2014 Aug 15;5(4):444-70
pubmed: 25126392
Am J Physiol Heart Circ Physiol. 2020 Apr 1;318(4):H820-H829
pubmed: 32083972